Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,595 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Efficacy of 48-week clevudine therapy for chronic hepatitis B].
Kim MH, Kim KA, Lee JS, Lee HW, Kim HJ, Yun SG, Kim NH, Bae WK, Moon YS. Kim MH, et al. Among authors: kim hj, kim ka, kim nh. Korean J Hepatol. 2009 Sep;15(3):331-7. doi: 10.3350/kjhep.2009.15.3.331. Korean J Hepatol. 2009. PMID: 19783882 Korean.
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14).
Lee CK, Chon HJ, Cheon J, Lee MA, Im HS, Jang JS, Kim MH, Park S, Kang B, Hong M, Kim JW, Park HS, Kang MJ, Park YN, Choi HJ. Lee CK, et al. Among authors: kim mh, kim jw. Lancet Gastroenterol Hepatol. 2023 Jan;8(1):56-65. doi: 10.1016/S2468-1253(22)00335-1. Epub 2022 Oct 31. Lancet Gastroenterol Hepatol. 2023. PMID: 36328033 Clinical Trial.
A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15).
Baek SK, Jeong JH, Jung K, Ahn HK, Kim MH, Sohn J, Park IH, Ahn JS, Lee DW, Im SA, Sim SH, Lee KS, Hyun Kim J, Shim HJ, Chae Y, Koh SJ, Lee H, Lee J, Byun JH, Seol Y, Lee EM, Jee HJ, An H, Park EB, Suh YJ, Lee KE, Park YH; Korean Cancer Study Group (KCSG). Baek SK, et al. Among authors: kim mh. Ther Adv Med Oncol. 2024 Jan 28;16:17588359231225029. doi: 10.1177/17588359231225029. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38288157 Free PMC article.
Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer.
Park C, Suh KJ, Kim SH, Lee KH, Im SA, Kim MH, Sohn J, Jeong JH, Jung KH, Lee KE, Park YH, Kim HJ, Cho EK, Choi IS, Noh SJ, Shin I, Cho DY, Kim JH. Park C, et al. Among authors: kim hj, kim sh, kim mh, kim jh. Cancer Immunol Immunother. 2024 Aug 6;73(10):197. doi: 10.1007/s00262-024-03782-7. Cancer Immunol Immunother. 2024. PMID: 39105849 Free PMC article. Clinical Trial.
Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16).
Kim SH, Im SA, Suh KJ, Lee KH, Kim MH, Sohn J, Park YH, Kim JY, Jeong JH, Lee KE, Choi IS, Park KH, Kim HJ, Cho EK, Park SY, Kim M, Kim JH. Kim SH, et al. Among authors: kim jy, kim hj, kim m, kim mh, kim jh. Eur J Cancer. 2023 Dec;195:113386. doi: 10.1016/j.ejca.2023.113386. Epub 2023 Oct 14. Eur J Cancer. 2023. PMID: 37890351 Free article. Clinical Trial.
Could cough hypersensitivity symptom profile differentiate phenotypes of chronic cough?
Kim MY, Won HK, Oh JY, Lee JH, Jo EJ, Kang SY, Lee JH, Lee SE, Kang N, Kim YC, Lee HY, An J, Yoo Y, Shim JS, Park SY, Park HK, Kim MH, Kim SH, Kim SH, Chang YS, Kim SH, Lee BJ, Birring SS, Song WJ. Kim MY, et al. Among authors: kim mh. ERJ Open Res. 2024 Nov 11;10(6):00260-2024. doi: 10.1183/23120541.00260-2024. eCollection 2024 Nov. ERJ Open Res. 2024. PMID: 39534772 Free PMC article.
4,595 results